New hope for tough thyroid cancers: drug XL092 targets resistant tumors
NCT ID NCT06959641
First seen May 23, 2026 · Last updated May 23, 2026
Summary
This study tests a new drug called XL092 in people with advanced thyroid cancer that no longer responds to standard radioiodine therapy. The drug works by blocking a protein that helps cancer cells grow. Researchers want to see if it can slow or stop the cancer from spreading, and they are looking for 33 participants to join.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY DIFFERENTIATED THYROID GLAND CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Harbor-UCLA Medical Center
RECRUITINGTorrance, California, 90502, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Northwestern University
RECRUITINGChicago, Illinois, 60611, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.